HOUSTON, July 6, 2020 — Physician-investigators at Johns Hopkins University Hospital report on the promising data of treatment of COVID-19 induced acute respiratory distress syndrome with allogeneic, cord blood derived T-regulatory (Treg) cell therapy (manufactured by Cellenkos®), published in peer reviewed journal of Annals of Internal Medicine. Both patients were critically ill and intubated (one on ECMO). Both had failed Tociluzimab (Actemra, Roche) and had multiorgan failure. Patients received cell therapy under FDA Emergency Use IND for up to 3 doses. [Read more…]
B-MoGen Biotechnologies, a Bio-Techne Company, Announces Opening of 2 Class 7 Clean Suites for Cellular Therapy Manufacturing
Contract Development & Manufacturing (CDMO):
B-MoGen’s ISO 7 cleanrooms now open for business
B-MoGen Biotechnologies, a unit of Bio-Techne, is proud to announce new cGMP cellular therapy manufacturing capacity for Phase I and Phase II clinical trials.
Luminary Therapeutics and Case Western Reserve University Enter Formal Collaboration for Development of BAFF CAR
Luminary Tx and CWRU enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome
MINNEAPOLIS, MN, USA, July 7, 2020– Luminary Therapeutics (Luminary Tx) and Case Western Reserve University have entered into a formal collaboration agreement that includes an option for Luminary to exclusively license a novel BAFF target for use in CAR-T (chimeric antigen receptor T cells) constructs. [Read more…]
Aspire Health Science LLC, Announces Release of ACP-01 Midpoint Analysis to Hemostemix Inc.
ORLANDO, Fla., July 6, 2020 – Aspire Health Science, LLC (the “Company” or “Aspire”), is an FDA registered cGMP manufacturing facility specializing in the research, development, and manufacturing of cell-based therapies. [Read more…]
Off-the-shelf NK cells in hematologic malignancies and oncology
Key Points:
- Natural killer (NK) cells represent innate immune cells with potent antitumor activity.
- Glycostem Therapeutics has established an innovative production process that yields high numbers of allogeneic NK cells with potent activity towards both hematologic and solid malignancies which can be used “off-the-shelf”.
- In a first-in-human phase I study in elderly patients with acute myeloid leukemia, these NK cells were well tolerated, had a favorable toxicity profile and were associated with promising efficacy.
- The possibility to genetically engineer the NK cells with chimeric antigen receptors or T cell receptors offers additional opportunities in immuno-oncology.
- « Previous Page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- …
- 62
- Next Page »